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Section A 
Short Essay Questions 
Total Number of Marks for this section: 90 Marks  
 
Answer this section in the Answer Booklet provided. 
 
Answer any SIX of the seven questions 
 
Marks for each question are indicated.  
Suggested Time allocation for Section A: 90 minutes 
 
Question 1 
(a)  Describe the ideal procedure for managing ST-elevation myocardial infarction 
(STEMI, a subclass of acute coronary syndrome). 
Your description should include symptom recognition, important diagnostic 
tests and analytical tool(s) available, treatment options and the justification for 
your recommendation, how to implement your suggested treatment options, 
and important factors that need to be taken into consideration. 
(b)  Outline the differences in the management of STEMI and angina. 




Describe osteoporosis and the current recommendation for its management.  
Your answer should include the pathophysiology of osteoporosis, risk factors that 
predispose an individual to osteoporosis, potential complications due to 
osteoporosis, mode of action of pharmacotherapies available, and important factors 
that need to be considered while managing osteoporosis. 




Compare and contrast these medical conditions: Asthma and Chronic Obstructive 
Pulmonary Disease (COPD).  
Your description should include the pathogenesis, any risk factors that predispose 
an individual to these disorders, clinical presentations, prognosis, management 
options, and important treatment considerations. 
 (15 Marks) 
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Question 4 
Mr RF is a 57 year-old male with a medical history of hypertension, atrial fibrillation 
(AF), type II diabetes (DM2), and chronic kidney disease (CKD). His CKD has been 
deteriorating, and now he is diagnosed with end stage renal failure (eGFR is about 
2-3 mL/min/1.73m2). Kidney transplant has been considered, but no suitable kidney 
donor is identified among his family members.  
Considering the scenario of Mr RF, what are the options available for managing his 
end stage CKD? Your answer should include: 
• A brief discussion and comparison of the advantages and limitations of each 
option. 
• Your recommendation which you think is the most suitable for Mr RF, and 
justify your answers. 
• Other management or monitoring procedures that is required for Mr RF, if he 
follows your recommendation. 




(a) Describe the different types of stroke (CVA) 
Your answer should include the pathogenesis, risk factors that predispose an 
individual to CVA, clinical presentations, management options, and treatment 
considerations. 
(b) What is the difference between CVA and transient ischemic attack (TIA)? 




(a) What is meant by acute kidney injury (AKI)? Describe the different types of 
AKI. 
Your answer should include the pathogenesis, risk factors that predispose an 
individual to AKI, clinical presentations, management options, and important 
treatment considerations. 
(b) Discuss the concept of acute-on-chronic renal failure and its clinical 
significant. 
 (10 + 5 = 15 Marks) 
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Question 7 
Briefly describe any TWO of the following medical conditions: 
• Hypovolemic shock 
• Thalassemia 
• Heart block (AV block) 
Your discussion should include the pathophysiology, risk factors that predispose an 
individual to these disorders, clinical presentations, key diagnostic tools available, 
treatment options, and important factors which need to be considered while 
managing these conditions. 
(7.5 + 7.5 = 15 Marks) 
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Section B 
Case Study Based Questions 
Total Number of Marks for this section: 90 Marks 
 
This section should be answered in the Answer Booklet provided. 
 
Answer ALL questions 
 
Marks for each question are indicated.  
Suggested Time allocation for Section B: 90 minutes 
 
Question 8 
Mr AA is a 79-year-old male living in a retirement home village. He does not need 
much assistance from the nursing staffs for his daily living activities. He moved into 
the retirement home village about 2 years ago after his wife passed away. Mr AA 
does not usually participate in much physical activities, but he often goes camping 
and fishing with his children and grandchildren when they visit.  
Mr AA had a mild upper respiratory tract infection (common cold) during the 
weekend, and was experiencing some shortness of breath and chest discomfort. He 
presents to his doctor’s clinic on Monday morning when the symptoms become 
more severe despite what he describes as “the cold has gone”. He also complains 
about some light headaches. 
On examination, the doctor notices significant rales (crepitations) and reduced air 
entry during his chest examination. His heart rate is increased and irregular 
(ventricular rate is 113 bpm, where his previous base line HR is 75-90).  
Other vital signs are as follow: BP = 146/84 mmHg; RR = 30; Temperature = 37.1°C; 
SatO2 = 87%; BSL (random) = 10.4 mmol/L; FEV1 = 1.8 L (62% predicted) 
 
Mr AA’s medical history: 
• Hypertension  
• COPD  
• TIA (2007) 
• Atrial fibrillation (AF, since 2001) 
• Gastro-oesophageal reflux disease (GORD) 
• Type II diabetes mellitus 
• Chronic renal failure (baseline eGFR = 50-60 mL/min/1.73m2) 
• Osteoarthritis (mainly affect the knee) 
• Depression 
• Congestive cardiac failure (diagnosed in 2012) 
• Osteopaenia  
Mr AA’s medication history:  
• Candesartan  16 mg mane 
• Seretide® accuhaler 250/50 µg i mane 
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• Salbutamol MDI 100 µg ii prn 
• Rivaroxiban  15 mg nocte 
• Temazepam  10 mg nocte 
• Perindopril  5 mg daily 
• Amlodipine  5 mg daily 
• Frusemide  40 mg mane 
• Panadol Osteo®  ii tds 
• Metformin  1g bd 
• Esomeprazole  20 mg daily 
• Multivitamin  i daily 
• Caltrate®  600 mg daily 
 
Accurate information regarding Mr AA’s family history is not available, except that 
his father passed away due to some ‘heart problem’ while serving in the army during 
the Second World War, and that his younger sister also has DM2 and heart disease. 
Mr AA is an ex-smoker (with multiple relapses), overweight (93kg; 181 cm tall) and 




(a) Based on the information above, what are the potential diagnoses for Mr AA’s 
current clinical presentation? Name FOUR (4) of the most likely diagnoses, 




(b) Explain your reason for suggesting these potential diagnoses. Discuss the 
signs and symptoms (in Mr AA) and risk factors which support the likelihood 




(c) Suggest diagnostic tests and/or clinical examinations (if any) that are 
routinely performed to confirm and/or to exclude each of your potential 
diagnoses in Q8a.  
In your answer, discuss the data / value of these tests that are helpful for your 
diagnoses, and the accuracy and limitations. If applicable, identify any 
factor(s) in Mr AA which may interfere with the test results.  
(4 Marks) 
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Mr AA’s is admitted into the hospital immediately and his blood and urine sample are 
taken. During the following 12 hours, Mr AA’s condition does not appear to change 
much, and all vital signs appear to be stable. His laboratory test results are:  
U&E 
• Na  129 (135 – 145 mmol/L) 
• K  3.7 (3.5 – 4.5 mmol/L) 
• Cl  84  (98 – 103 mmol/L) 
• Urea 15  (3 – 8 mmol/L) 
• Cr  138  (65 -105 µmol/L) 
• eGFR 43.1 (>90 mL/min/1.73m2) 
FBE 
• Hb  145 (135 – 185 g/L) 
• RCC  4.6  (4.5 – 5.5 x 1012 L) 
• Hct 38  (42-52 %) 
• MCV 83  (80-100 fL) 
• Platelet 320 (150-400 x 109/L) 
• WCC  11.5 (4.0-10.0 x 109/L) 
• Neutrophil 8.8  (2.0-7.0 x 109/L) 
Others 
• Troponin  negative  (<0.01 µg/L) 
• D-dimer 210  (<500 µg/L) 
• HbA1c 8.1 (<7 %) 
• PT 17.2 (11.0 – 13.0 sec) 
• INR 1.2 (0.9 – 1.1) 
 
CXR reveals right and left lower lobe consolidation and an enlarged heart. Mr AA is 
diagnosed with acute exacerbation of HF. 
 
Questions: 
(d). Discuss the development of acute exacerbation of HF in Mr AA. 
Your discussion should include contributing factors, pathophysiology and 
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(e) Discuss the adequacy of diabetes control in Mr AA, and how it would impact 
on his current health condition. 
Your discussion should include both the immediate consequences and the 




(f) Discuss the use of rivaroxaban in Mr AA, and how the PT and INR tests 




(g) Recommend a treatment plan(s) to manage Mr AA’s current conditions. Your 
recommendation should clearly identify both the immediate and the long term 
treatment plans. 
Justify your recommendation and explain how it benefits Mr AA.  
(6 + 12 = 18 Marks) 
(Total: 45 Marks) 
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Question 9 
Miss BB is a 26 year-old female with type I diabetes mellitus (DM1). She has been on 
insulin therapy since she was 15 years old. During a routine medical check-up, her BP 
is 161/94 mmHg. The elevation of her BP was first noticed about 3 months ago, but 
before that, she had optimum BP control. A serum lipid test result from her previous 
medical check-up is available. 
• Total cholesterol  5.7 (<5.5 mmol/L) 
• LDL 4.1 (2.0 – 3.4 mmol/L) 
• HDL  0.8 (> 1.0 mmol/L) 
• TG  1.8 (<1.7 mmol/L) 
 
Medical history as follow: 
• Type I diabetes (since 2003) 
• Asthma 
• Acute glomerulonephritis (6 months ago) 
• Anaemia (secondary to menorrhagia – heavy menstrual period) 
• Anxiety disorder 
 
Medication history:  
• Montelukast  10 mg nocte 
• Sertraline  100 mg daily 
• Diclofenac  50mg bd prn 
• Microgynon® 20 ED (ethinyloestradiol/ levonorgestrel) 
  i daily 
• Salbutamol MDI  100mcg ii – iv puffs prn 
• Budesonide/ eformoterol turbuhaler  400/12 bd 
• Ferrograd® C(Ferrous sulfate + vit C) i mane 
• Oxazepam  15 mg qid prn 
• NovoMix® 30 (30/70 insulin aspart)  5-10 U bd mdu 
• NovoRapid® (insulin aspart)  3-6 U prn 
• Lantus® (insulin glargine)  8 U nocte 
 
Family history: Miss BB’s mother has type II diabetes (DM2), and her father had an 
acute coronary event (non-STEMI-ACS) 2 years ago. 
 
Social history: Miss BB is about 83 kg and 173 cm tall, a current smoker and consumes 




(a) Discuss Miss BB’s risk of developing cardiovascular disease, and recommend a 
management plan. Explain how your recommendation can reduce her risk.  
(6 Marks) 
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Six years later, Miss BB (now Ms BB, 32 year-old) is now married. Soon after returning 
from her honeymoon, Ms BB visits her GP because she experiences increasing 
symptoms of joint pain affecting her wrists, knees and fingers. She also complains 
about acute gout on her left toe.  
Ms BB had a few incidents of gouts in the past 3 years, and she is currently taking 
allopurinol 200 mg daily, on top of her other medications as you have recommended in 
Q9a. She has also successfully lost a bit of weight prior to the wedding, and she 
currently weighs 76 kg. 
On examination, Ms BB’s left toe appears swollen with significant inflammation. Her 
wrists and knees are red and warm to touch, but her fingers appear relatively normal. 
Other vital signs are as follow: 
BP = 146/90 mmHg; HR = 91 bpm; RR = 18; Temperature = 36.7°C; SaO2 = 99%; BSL 
(random) = 8.9 mmol/L, PEF = 450 L/min (92% predicted) 
 
Blood samples are collected and the test results as follow: 
U & E 
• Na  142 (135 – 145 mmol/L) 
• K  4.1 (3.5 – 4.5 mmol/L) 
• Cl  101 (98 – 103 mmol/L) 
• Urea  10 (3 – 8 mmol/L) 
• Cr  85 (65 – 105 µmol/L) 
• eGFR 67 (>90 mL/min/1.73m2) 
FBE 
• Hb 136 (120 – 160 g/L) 
• RCC 4.3 (4.0 – 5.0 x 1012/L) 
• Hct  47 (36 – 48 %) 
• Platelet 510 (150-450 x109/L) 
• MCV  109 (80 – 100 fL) 
• WCC  11.5 (4.0-10.0 x109/L) 
• Neutrophil  9.0  (2.0-7.0 x109/L) 
Other tests 
• Ketone -ve (<0.4 mmol/L) 
• HbA1c 6.8  
• Uric acid 0.48 (<0.36 mmol/L) 
• CRP 102 (<3 mg/L) 
• Rheumatoid factor 32 (<15 IU/mL) 
• Syphilis serology  -ve 
• Gonorrhoea PCR -ve 
• Blood MCS no growth 
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Questions: 
(b) Discuss the development of rheumatoid arthritis in Ms BB. 
Your discussion should include contributing factors, pathophysiology, and its 




(c) Discuss the development of acute gout in Ms BB. 
Your discussion should include contributing factors, pathophysiology, and its 




(d) Discuss the other significant findings (other than the rheumatoid arthritis and 
gout) in Ms BB’s medical history or laboratory test results.  
Based on these information, how well do you rate the management of her 




(e) What treatment plan would you recommend for the management of Ms BB’s 
current conditions? Explain and justify your recommendations. 
Note: please identify immediate and long term treatment plans if applicable, and 
provide relevant details. 
(6 + 12 = 18 Marks) 
 
 
Six months after the diagnosis of rheumatoid arthritis, Ms BB has achieved clinical 
remission with pharmacological therapies. Considering her age, Ms BB is keen to get 




(f) What factors need to be considered or treatment need to be modified before 
Ms BB becomes pregnant? 
 (5 Marks) 
 (Total: 45 Marks) 
(END OF EXAM PAPER) 
